Periampullary Cancer Clinical Trial
— XandTXOfficial title:
Pancreatic Head Resection or Total Pancreatectomy With Islet Autotransplantation (IAtx) in Patients With Periampullary Cancer and High Risk Profile for the Development of Postoperative Pancreatic Fistula (POPF)
The primary objective of this clinical trial is to evaluate whether primary total pancreatectomy with simultaneous islet autotransplantation compared with pancreatic head resection (alone) can reduce perioperative morbidity and time to initiation of adjuvant therapy in patients with a high-risk constellation for pancreatic fistulas.
Status | Not yet recruiting |
Enrollment | 32 |
Est. completion date | January 2028 |
Est. primary completion date | January 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - suspected or confirmed periampullary carcinoma (tumor) and indication for PPPD (pylorus-preserving pancreaticoduodenectomy) or Whipple surgery - high-risk profile for the development of a postoperative pancreatic fistula (POPF) after pancreatic head resection: soft pancreas and Pancreatic duct diameter < 3 mm (preoperative and intraoperative confirmation) - written informed consent of the participant after successful Informed consent Exclusion Criteria: - patients on whom another procedure is to be performed simultaneously in addition to PPPD or Whipple surgery - confirmed other primary tumor - previous transplantation of an organ or tissue - known infection with HIV (HIV antibodies) - positive hepatitis C antibodies, positive hepatitis B surface antigens and hepatitis Bc antibodies - insulin-treated diabetes mellitus - history of hypersensitivity to any of the drugs used or their ingredients or to drugs with a similar chemical structure - concurrent participation in another clinical trial (incl. within the last 4 weeks prior to inclusion). - addiction or other medical conditions that do not allow the subject to understand the nature and not be able to appreciate the nature, scope and possible consequences of the trial - pregnant or breastfeeding women - women of childbearing age, except for women who meet the following criteria: 1. Post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with Serum FSH > 40 U/ml) 2. Post-operative (6 weeks after bilateral ovariectomy with or without hysterectomy) 3. Regular and correct use of a contraceptive method with an failure rate < 1% per year 4. Sexual abstinence 5. Vasectomy of the partner - evidence that the patient is unlikely to comply with the protocol |
Country | Name | City | State |
---|---|---|---|
Germany | University Hospital Carl Gustav Carus Technische Universität Dresden | Dresden |
Lead Sponsor | Collaborator |
---|---|
Technische Universität Dresden | German Cancer Research Center, KKS Dresden |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Duration between surgery and time "fit for adjuvant treatment" (postoperative day X) | Time (days) between surgery and the date of certified fitness to begin adjuvant therapy, confirmed by an oncology consult, starting at day of discharge, than assessed at POD 90, POD 180, POD 365, 24 months | From day of discharge until confirmed fitness for adjuvant treatment or 24 months, whichever came first | |
Secondary | Comparison of actual start of adjuvant therapy in both arms | Postoperative day on which adjuvant therapy was started | From POD 90 until actual start of therapy or 24 months whichever came first | |
Secondary | Rate of peri-operative morbidity/mortality acc. to Clavien-Dindo classification | Rate of peri-operative morbidity/mortality will be assessed acc. to Clavien-Dindo classification | After enrolment of the patient until 24 months after intervention | |
Secondary | Rate of (serious) adverse events | Rate of (serious) adverse events, according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE Version 5.0, 2017) | After randomization of the patient until 24 months after intervention | |
Secondary | Patient reported outcomes: Quality of life EORTC QLQ C30 questionnaire | The QoL analyses will include QoL mean values, QoL response. EORTC QLQ C30 contains 30 questions28 questions regarding body fitness, daily routines, restrictions at work and hobby, appetite, fatigue, cough, breathlessness, pain, tiredness, and body conditions from (1) to (4); 1 (not a bit), 2 (little), 3 (moderate), 4 (much).
2 questions regarding state of health and Quality of life with a horizontal rating from 1 to 7; 1 (very bad), 7 (excellent).; assessed at POD 90, POD 180, POD 365, and 24 months after surgery |
From date of screening until 24 months after intervention | |
Secondary | Patient reported outcomes: Quality of life EORTC PAN26 questionnaire | The QoL analyses will include QoL mean values, QoL response. EORTC QLQ PAN26 contains 30 questions regarding pain, nutrition, body fitness, sexuality, from (1) to (4); 1 (not a bit), 2 (little), 3 (moderate), 4 (much).
28 questions regarding body fitness, daily routines, restrictions at work and hobby, appetite, fatigue, cough, breathlessness, pain, tiredness, and body conditions from (1) to (4); 1 (not a bit), 2 (little), 3 (moderate), 4 (much); , assessed at POD 90, POD 180, POD 365, and 24 months after surgery 2 questions regarding state of health and Quality of life with a horizontal rating from 1 to 7; 1 (very bad), 7 (excellent). |
From date of screening until 24 months after intervention | |
Secondary | Comparison of metabolic outcome in both arms: continuous glucose monitoring (CGM) | Metabolic outcome will be determined on continuous monitoring of glucose (CGM) in plasma (mmol/L) at every visit: Screening, POD 1, POD 3, day of discharge, POD 90, POD 180, POD 365 and 24 months after intervention | From date of screening until 24 months after intervention | |
Secondary | Comparison of metabolic outcome in both arms: glucagon | Metabolic outcome will be determined on the hormone glucagon in plasma at every visit: Screening, POD 1, POD 3, day of discharge, POD 90, POD 180, POD 365 and 24 months after intervention | From date of screening until 24 months after intervention | |
Secondary | Comparison of metabolic outcome in both arms: glycohemoglobin HbA1c | Metabolic outcome will be determined on glycohemoglobin (HbA1c in %) at every visit: Screening, POD 1, POD 3, day of discharge, POD 90, POD 180, POD 365 and 24 months after intervention | From date of screening until 24 months after intervention | |
Secondary | Comparison of metabolic outcome in both arms: C-peptide | Metabolic outcome will be determined on serum C-peptide (nmol/L) as measure for functionality of pancreas at every visit: Screening, POD 1, POD 3, day of discharge, POD 90, POD 180, POD 365 and 24 months after intervention | From date of screening until 24 months after intervention | |
Secondary | Comparison of metabolic outcome in both arms: fructosamine | Metabolic outcome will be determined on serum fructosamine (µmol/L) at every visit: Screening, POD 1, POD 3, day of discharge, POD 90, POD 180, POD 365 and 24 months after intervention | From date of screening until 24 months after intervention | |
Secondary | Comparison of metabolic outcome in both arms: insulin requirement | Metabolic outcome will be determined on requirement of insulin (yes/no) at every visit: Screening, POD 1, POD 3, day of discharge, POD 90, POD 180, POD 365 and 24 months after intervention | From date of screening until 24 months after intervention | |
Secondary | Comparison of metabolic outcome in both arms: number of hypoglycemic events | Metabolic outcome will be determined on number of hypoglycemic events (defined as value of blood glucose below 3.5 mmol/l) at every visit: Screening, POD 1, POD 3, day of discharge, POD 90, POD 180, POD 365 and 24 months after intervention | From date of screening until 24 months after intervention | |
Secondary | Comparison of metabolic outcome in both arms: severity of hypoglycemia | Metabolic outcome will be determined on severity of hypoglycemic events (decrease of blood glucose level) at every visit: Screening, POD 1, POD 3, day of discharge, POD 90, POD 180, POD 365 and 24 months after intervention | From date of screening until 24 months after intervention | |
Secondary | Comparison of long-term oncological course (24 months) in both arms: tumor markers | Within 24 months after intervention, oncological outcome is evaluated, as measured by tumor markers CA 19-9, CEA | 24 months after intervention | |
Secondary | Comparison of long-term oncological course (24 months) in both arms: recurrence | Within 24 months after intervention, oncological outcome is evaluated, as measured by recurrences of tumor shown in CT imaging | 24 months after intervention | |
Secondary | Comparison of long-term oncological course (24 months) in both arms: occurence of metastases | Within 24 months after intervention, oncological outcome is evaluated, as measured by metastases shown in CT imaging | 24 months after intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04095312 -
Clinical Study for Evaluating the Clinical Safety and Effectiveness of the Automated Robotic Robot, Revo-i Surgical Robot System (Model MSR-5100), Used for General Endoscopic Surgery.
|
N/A | |
Not yet recruiting |
NCT06009224 -
The Effect of ERAS on Pancreaticoduodenectomy (v2.0)
|
N/A | |
Recruiting |
NCT05155878 -
Prognostic Factors in Periampullary Tumors and Cysts
|
||
Recruiting |
NCT03724994 -
Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer
|
||
Recruiting |
NCT03063554 -
EUS BD vs ERCP TP for Pancreatic Cancer
|
N/A | |
Completed |
NCT03870698 -
Comparison of Functional Recovery Between Laparoscopic and Open Pancreaticoduodenectomy
|
N/A | |
Terminated |
NCT04311047 -
Preoperative Detection of Lymph Node Metastases in Pancreatic and Periampullary Carcinoma Using USPIO MRI
|
N/A | |
Not yet recruiting |
NCT06381882 -
The Role of the Human Microbiome in Patients After Pancreatic Resection.
|
||
Recruiting |
NCT03138213 -
Comparing Total Laparoscopic Versus Open Pancreaticoduodenectomy
|
N/A | |
Withdrawn |
NCT01913275 -
Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage Before Pancreaticoduodenectomy
|
N/A | |
Completed |
NCT04401722 -
Clinical Impact of Altitude Level on Surgical Outcomes of Pancreaticoduodenectomy
|
N/A | |
Completed |
NCT02787512 -
Preoperative Biliary Drainage With Metal Versus Plastic Stents in Periampullary Cancer
|
N/A | |
Completed |
NCT02900950 -
Multicolour Versus Monocolour Specimens Inking After Pancreaticoduodenectomy for Periampullary Cancer
|
N/A | |
Recruiting |
NCT06069297 -
Prehabilitation in Pancreatic Surgery
|
N/A | |
Completed |
NCT01789502 -
Comparison Between Fully Covered Metal Stents and Plastic Stents in Preoperative Biliary Drainage
|
N/A | |
Suspended |
NCT04714983 -
DNX-2440 for Resectable Colorectal Liver Metastasis
|
Phase 1 | |
Terminated |
NCT05289830 -
Escitalopram to Placebo in Patients With Localized Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT04289831 -
Preoperative Biliary Drainage in Patients With Operable Malignant Periampulary Tumors
|
N/A | |
Completed |
NCT00841607 -
Reconstruction Following Pancreaticoduodenectomy: A Randomized Clinical Trial of Pancreaticojejunostomy vs Pancreaticogastomy
|
N/A | |
Completed |
NCT04985071 -
Complication of Pancreatic Fistula and Bleeding After Pancreaticoduodenectomy in Treatment Periampullary Cancer
|